Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Exondys Approval: Measured Efficacy Outcomes Vs. Patient 'Anecdotes'

Dec 28 2016

• By Sue Sutter

Related Content

FDA's Fears Realized: Sponsors Pitching Investors 'Sarepta Model'

Oct 26 2016

Duchenne Group's Presentation Is Milestone For Patient Involvement

May 02 2016

Exondys 51 Clinical Development Timeline

Dec 28 2016

Exondys 51 Reviewers

Dec 28 2016

Eteplirsen Approval Reflected FDA's Conflict On Accelerated Approval – Former Sarepta CEO

Dec 28 2016

Duchenne Muscular Dystrophy: FDA Supports Broader Outcome Measures, Biomarkers

Jun 10 2015

Patient Advocacy With FDA Review Staff Will Be Tougher Post-Sarepta

Sep 23 2016

Accelerated Approval After Eteplirsen: A Lowered Bar Or A Unique Event?

Sep 21 2016

Eteplirsen Review Offers Lessons For FDA, Advocacy Groups, Industry

Sep 21 2016

Woodcock's Consideration of Sarepta Financial Issues Raises Eyebrows

Sep 20 2016

Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate

Sep 20 2016

Eteplirsen Review Timeline: CDER Director Was Involved Early And Often

Sep 20 2016

The Eteplirsen Approval: Former FDA Officials Weigh In On The Science

Sep 29 2016

Duchenne Development: Six-Minute Walk Losing Favor?

Sep 21 2016

21<sup>st</sup> Century Cures Revisions Tell FDA To Highlight ‘Patient Experience Data’

Nov 28 2016

Sarepta Pressured FDA On Eteplirsen Due To ‘Dire’ Finances, Gave Investors Rosier Picture

Nov 04 2016

Political Appointees Shouldn't Influence Approval Decisions, Califf Says

Oct 20 2016

No More Sarepta-Like Development, FDA Officials Say

Oct 20 2016

Exondys Approval: FDA Commissioner's Draft Decision Drew Internal Rebuke

Nov 03 2016

Sarepta’s Aftermath: FDA Staff Still Working Together, Califf Says

Nov 16 2016

Exondys 51’s Development: Was Placebo-Controlled Trial Possible?

Nov 16 2016

Patient-Driven Drug Development Requires New Transparency Policies

Nov 11 2016

Related Companies

Sarepta Therapeutics, Inc.

Additional Topics

Approvals Regulation Drug Review Profile BioPharmaceutical Neurology

More from Drug Review Profiles

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window